Advancements in Nanoparticle-Based Precision Drug Delivery: A Review of Development and Optimization for Targeted Therapy in Preclinical Models
Keywords:
Nanoparticles, Clinical applications, biological barriers, Systemic barriers, Microenvironmental barriers, Cellular barriers, Patient heterogeneity, Precision therapeutics, Personalized interventions, Optimization
Abstract
In recent years, the widespread adoption of nanoparticles has expanded across a broad spectrum of clinical domains. These nanoparticles have been specifically engineered to address the limitations associated with conventional therapeutics and to navigate various biological barriers—ranging from systemic to cellular levels—that manifest heterogeneity across different patient populations and disease states. The advent of precision treatments, wherein interventions are tailored to individual patients, has contributed to mitigating this variability among patients. Nonetheless, the predominant focus in current nanoparticle research remains on enhancing the uniformity of delivery systems. The realization of precision medicine appears imminent as lipid-based, polymeric, and inorganic nanoparticles are increasingly crafted with heightened precision, facilitating more individualized approaches to medication delivery. In this review, we delve into the advanced designs of nanoparticles employed in both precision and generalized applications, offering insights into their potential to advance precision medicine. Our discussion centers on the innovations in nanoparticle design aimed at overcoming various delivery challenges, suggesting that ingenious nanoparticle engineering holds promise for enhancing performance across a broad spectrum of delivery applications and facilitating tailored designs for specific therapeutic targets, ultimately leading to improved patient outcomes.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
PlumX Statistics
References
1. Aghebati‐Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., Aghebati‐Maleki, L., 2020. Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. Journal of Cellular Physiology, 235(3), pp.1962-1972.
2. Albanese, A., Tang, P.S. and Chan, W.C., 2012. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual Review of Biomedical Engineering, 14, pp.1-16.
3. Alexis, F., Pridgen, E., Molnar, L.K. and Farokhzad, O.C., 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics, 5(4), pp.505-515.
4. Allen, T.M. and Cullis, P.R., 2013. Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), pp.36-48.
5. Anselmo, A.C. and Mitragotri, S., 2019. Nanoparticles in the clinic: an update. Bioengineering & Translational Medicine, 4(1), pp.1-16.
6. Bae, Y.H. and Park, K., 2011. Targeted drug delivery to tumors: myths, reality and possibility. Journal of Controlled Release, 153(3), pp.198-205.
7. Barbosa, A.I., Rebelo, R., Reis, R.L., Bhattacharya, M. and Correlo, V.M., 2021. Current nanotechnology advances in diagnostic biosensors. Medical Devices & Sensors, 4(1), e10156.
8. Bertrand, N., Wu, J., Xu, X., Kamaly, N. and Farokhzad, O.C., 2014. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Advanced Drug Delivery Reviews, 66, pp.2-25.
9. Blanco, E., Shen, H. and Ferrari, M., 2015. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), pp.941-951.
10. Bravo-Vázquez, L.A., Méndez-García, A., Rodríguez, A.L., Sahare, P., Pathak, S., Banerjee, A. and Paul, S., 2023. Applications of nanotechnologies for miRNA-based cancer therapeutics: Current advances and future perspectives. Frontiers in Bioengineering and Biotechnology, 11.
11. Byrne, J.D., Betancourt, T. and Brannon-Peppas, L., 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews, 60(15), pp.1615-1626.
12. Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M.R., Miyazono, K. and Ueda, M., 2011. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumors depends on the size. Nature Nanotechnology, 6(12), pp.815-823.
13. Chauhan, V.P., Stylianopoulos, T., Boucher, Y. and Jain, R.K., 2011. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annual Review of Chemical and Biomolecular Engineering, 2, pp.281-298.
14. Cheng, Q., et al., 2020. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nature Nanotechnology, 15, pp.313–320.
15. Cho, K., Wang, X., Nie, S., Chen, Z.G. and Shin, D.M., 2008. Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research, 14(5), pp.1310-1316.
16. Clegg, J.R., Irwin, E.F., Peppas, N.A., 2019. Synthetic networks with tunable responsiveness, biodegradation, and molecular recognition for precision medicine applications. Science Advances, 5, eaax7946.
17. Culver, H.R., Clegg, J.R. and Peppas, N.A., 2017. Analyte-responsive hydrogels: intelligent materials for biosensing and drug delivery. Accounts of Chemical Research, 50(2), pp.170–178.
18. Danhier, F., Feron, O. and Préat, V., 2010. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), pp.135-146.
19. Davis, M.E., Chen, Z.G. and Shin, D.M., 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery, 7(9), pp.771-782.
20. Dobrovolskaia, M.A. and McNeil, S.E., 2007. Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2(8), pp.469-478.
21. Dreaden, E.C., Alkilany, A.M., Huang, X., Murphy, C.J. and El-Sayed, M.A., 2012. The golden age: gold nanoparticles for biomedicine. Chemical Society Reviews, 41(7), pp.2740-2779.
22. Farokhzad, O.C. and Langer, R., 2009. Impact of nanotechnology on drug delivery. ACS Nano, 3(1), pp.16-20.
23. Hrkach, J., Von Hoff, D., Mukkaram Ali, M., Andrianova, M., Sawant, R., McDonnell, K., Kanapathipillai, M., Liu, L., Wildstein, C., Couvreur, P. and Langer, R., 2012. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine, 4(128), pp.128ra39-128ra39.
24. Hua, S., de Matos, M.B.C., Metselaar, J.M. and Storm, G., 2018. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Frontiers in Pharmacology, 9, p.790.
25. Irvine, D.J. and Dane, E.L., 2020. Enhancing cancer immunotherapy with nanomedicine. Nature Reviews Immunology, 20(5), pp.321-334.
26. Jain, R.K. and Stylianopoulos, T., 2010. Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology, 7(11), pp.653-664.
27. Jampílek, J. and Kráľová, K., 2019. Recent advances in lipid nanocarriers applicable in the fight against cancer. In: Nanoarchitectonics in Biomedicine, pp.219-294.
28. Jokerst, J.V., Lobovkina, T., Zare, R.N. and Gambhir, S.S., 2011. Nanoparticle PEGylation for imaging and therapy. Nanomedicine, 6(4), pp.715-728.
29. Joseph, T.M., Kar Mahapatra, D., Esmaeili, A., Piszczyk, L., Hasanin, M.S., Kattali, M., Thomas, S., 2023. Nanoparticles: Taking a unique position in medicine. Nanomaterials, 13(3), p.574.
30. Kamaly, N., Xiao, Z., Valencia, P.M., Radovic-Moreno, A.F. and Farokhzad, O.C., 2012. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chemical Society Reviews, 41(7), pp.2971-3010.
31. Knight, F.C., Gilchuk, P., Kumar, A., et al., 2019. Mucosal immunization with a pH-responsive nanoparticle vaccine induces protective CD8+ lung-resident memory T cells. ACS Nano, 13(3), pp.2094-2103.
32. Kou, L., Sun, J., Zhai, Y., He, Z., 2018. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Frontiers in Pharmacology, 9, pp.1–16.
33. Kumari, N. and Choi, S.H., 2022. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. Journal of Experimental & Clinical Cancer Research, 41(1), p.68.
34. Liu, J., Liu, Z., Pang, Y. and Zhou, H., 2022. The interaction between nanoparticles and the immune system: application in the treatment of inflammatory diseases. Journal of Nanobiotechnology, 20(1), p.127.
35. Mitragotri, S., Anderson, D.G., Chen, X., Chow, E.K., Ho, D., Kabanov, A.V., Karp, J.M., Kataoka, K., Mirkin, C.A., Petrosko, S.H. and Shi, J., 2017. Drug delivery research for the future: expanding the nano horizons and beyond. Journal of Controlled Release, 246, pp.183–184.
36. Nikandish, M., Wang, H., Bao, X. and Nikandish, M., 2024. Enhancing Drug Delivery Precision: Development and Optimization of Nanoparticle-Based Formulations for Targeted Therapy in Preclinical Models. ESI Preprints, 26, pp.232-232.
37. Panyam, J. and Labhasetwar, V., 2012. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews, 64(3), pp.61-71.
38. Park, K., 2013. Facing the truth about nanotechnology in drug delivery. ACS Nano, 7(9), pp.7442-7447.
39. Paul, W. and Sharma, C.P., 2020. Inorganic nanoparticles for targeted drug delivery. In: Biointegration of Medical Implant Materials, pp.333-373.
40. Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R. and Langer, R., 2007. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), pp.751-760.
41. Petros, R.A. and DeSimone, J.M., 2010. Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), pp.615-627.
42. Rehman, N. and Pandey, A., 2022. Introduction to nanotherapeutics: a synthetic preview. In: Nanotherapeutics in Cancer, pp.1-22.
43. Shi, J., Kantoff, P.W., Wooster, R. and Farokhzad, O.C., 2017. Cancer nanomedicine: progress, challenges, and opportunities. Nature Reviews Cancer, 17(1), pp.20-37.
44. Svenson, S. and Tomalia, D.A., 2005. Dendrimers in biomedical applications—reflections on the field. Advanced Drug Delivery Reviews, 57(15), pp.2106-2129.
45. Thakuria, A., Kataria, B. and Gupta, D., 2021. Nanoparticle-based methodologies for targeted drug delivery—an insight. Journal of Nanoparticle Research, 23(4), p.87.
46. Torchilin, V.P., 2005. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), pp.145-160.
47. Wagner, A.M., Gran, M.P. and Peppas, N.A., 2018. Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery. Acta Pharmaceutica Sinica B, 8(2), pp.147–164.
48. Wechsler, M.E., Vela Ramirez, J.E. and Peppas, N.A., 2019. Nanoparticle-mediated drug delivery for the treatment of Alzheimer’s disease: crossing the blood–brain barrier. Industrial & Engineering Chemistry Research, 58(30), pp.13554-13564.
49. Wilhelm, S., Tavares, A.J., Dai, Q., Ohta, S., Audet, J., Dvorak, H.F. and Chan, W.C., 2016. Analysis of nanoparticle delivery to tumors. Nature Reviews Materials, 1(5), p.16014.
50. Zhuang, J., Holay, M., Park, J.H., Fang, R.H., Zhang, J. and Zhang, L., 2019. Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy. Theranostics, 9(25), pp.7826-7848.
2. Albanese, A., Tang, P.S. and Chan, W.C., 2012. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual Review of Biomedical Engineering, 14, pp.1-16.
3. Alexis, F., Pridgen, E., Molnar, L.K. and Farokhzad, O.C., 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics, 5(4), pp.505-515.
4. Allen, T.M. and Cullis, P.R., 2013. Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), pp.36-48.
5. Anselmo, A.C. and Mitragotri, S., 2019. Nanoparticles in the clinic: an update. Bioengineering & Translational Medicine, 4(1), pp.1-16.
6. Bae, Y.H. and Park, K., 2011. Targeted drug delivery to tumors: myths, reality and possibility. Journal of Controlled Release, 153(3), pp.198-205.
7. Barbosa, A.I., Rebelo, R., Reis, R.L., Bhattacharya, M. and Correlo, V.M., 2021. Current nanotechnology advances in diagnostic biosensors. Medical Devices & Sensors, 4(1), e10156.
8. Bertrand, N., Wu, J., Xu, X., Kamaly, N. and Farokhzad, O.C., 2014. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Advanced Drug Delivery Reviews, 66, pp.2-25.
9. Blanco, E., Shen, H. and Ferrari, M., 2015. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), pp.941-951.
10. Bravo-Vázquez, L.A., Méndez-García, A., Rodríguez, A.L., Sahare, P., Pathak, S., Banerjee, A. and Paul, S., 2023. Applications of nanotechnologies for miRNA-based cancer therapeutics: Current advances and future perspectives. Frontiers in Bioengineering and Biotechnology, 11.
11. Byrne, J.D., Betancourt, T. and Brannon-Peppas, L., 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews, 60(15), pp.1615-1626.
12. Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M.R., Miyazono, K. and Ueda, M., 2011. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumors depends on the size. Nature Nanotechnology, 6(12), pp.815-823.
13. Chauhan, V.P., Stylianopoulos, T., Boucher, Y. and Jain, R.K., 2011. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annual Review of Chemical and Biomolecular Engineering, 2, pp.281-298.
14. Cheng, Q., et al., 2020. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nature Nanotechnology, 15, pp.313–320.
15. Cho, K., Wang, X., Nie, S., Chen, Z.G. and Shin, D.M., 2008. Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research, 14(5), pp.1310-1316.
16. Clegg, J.R., Irwin, E.F., Peppas, N.A., 2019. Synthetic networks with tunable responsiveness, biodegradation, and molecular recognition for precision medicine applications. Science Advances, 5, eaax7946.
17. Culver, H.R., Clegg, J.R. and Peppas, N.A., 2017. Analyte-responsive hydrogels: intelligent materials for biosensing and drug delivery. Accounts of Chemical Research, 50(2), pp.170–178.
18. Danhier, F., Feron, O. and Préat, V., 2010. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), pp.135-146.
19. Davis, M.E., Chen, Z.G. and Shin, D.M., 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery, 7(9), pp.771-782.
20. Dobrovolskaia, M.A. and McNeil, S.E., 2007. Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2(8), pp.469-478.
21. Dreaden, E.C., Alkilany, A.M., Huang, X., Murphy, C.J. and El-Sayed, M.A., 2012. The golden age: gold nanoparticles for biomedicine. Chemical Society Reviews, 41(7), pp.2740-2779.
22. Farokhzad, O.C. and Langer, R., 2009. Impact of nanotechnology on drug delivery. ACS Nano, 3(1), pp.16-20.
23. Hrkach, J., Von Hoff, D., Mukkaram Ali, M., Andrianova, M., Sawant, R., McDonnell, K., Kanapathipillai, M., Liu, L., Wildstein, C., Couvreur, P. and Langer, R., 2012. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine, 4(128), pp.128ra39-128ra39.
24. Hua, S., de Matos, M.B.C., Metselaar, J.M. and Storm, G., 2018. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Frontiers in Pharmacology, 9, p.790.
25. Irvine, D.J. and Dane, E.L., 2020. Enhancing cancer immunotherapy with nanomedicine. Nature Reviews Immunology, 20(5), pp.321-334.
26. Jain, R.K. and Stylianopoulos, T., 2010. Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology, 7(11), pp.653-664.
27. Jampílek, J. and Kráľová, K., 2019. Recent advances in lipid nanocarriers applicable in the fight against cancer. In: Nanoarchitectonics in Biomedicine, pp.219-294.
28. Jokerst, J.V., Lobovkina, T., Zare, R.N. and Gambhir, S.S., 2011. Nanoparticle PEGylation for imaging and therapy. Nanomedicine, 6(4), pp.715-728.
29. Joseph, T.M., Kar Mahapatra, D., Esmaeili, A., Piszczyk, L., Hasanin, M.S., Kattali, M., Thomas, S., 2023. Nanoparticles: Taking a unique position in medicine. Nanomaterials, 13(3), p.574.
30. Kamaly, N., Xiao, Z., Valencia, P.M., Radovic-Moreno, A.F. and Farokhzad, O.C., 2012. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chemical Society Reviews, 41(7), pp.2971-3010.
31. Knight, F.C., Gilchuk, P., Kumar, A., et al., 2019. Mucosal immunization with a pH-responsive nanoparticle vaccine induces protective CD8+ lung-resident memory T cells. ACS Nano, 13(3), pp.2094-2103.
32. Kou, L., Sun, J., Zhai, Y., He, Z., 2018. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Frontiers in Pharmacology, 9, pp.1–16.
33. Kumari, N. and Choi, S.H., 2022. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. Journal of Experimental & Clinical Cancer Research, 41(1), p.68.
34. Liu, J., Liu, Z., Pang, Y. and Zhou, H., 2022. The interaction between nanoparticles and the immune system: application in the treatment of inflammatory diseases. Journal of Nanobiotechnology, 20(1), p.127.
35. Mitragotri, S., Anderson, D.G., Chen, X., Chow, E.K., Ho, D., Kabanov, A.V., Karp, J.M., Kataoka, K., Mirkin, C.A., Petrosko, S.H. and Shi, J., 2017. Drug delivery research for the future: expanding the nano horizons and beyond. Journal of Controlled Release, 246, pp.183–184.
36. Nikandish, M., Wang, H., Bao, X. and Nikandish, M., 2024. Enhancing Drug Delivery Precision: Development and Optimization of Nanoparticle-Based Formulations for Targeted Therapy in Preclinical Models. ESI Preprints, 26, pp.232-232.
37. Panyam, J. and Labhasetwar, V., 2012. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews, 64(3), pp.61-71.
38. Park, K., 2013. Facing the truth about nanotechnology in drug delivery. ACS Nano, 7(9), pp.7442-7447.
39. Paul, W. and Sharma, C.P., 2020. Inorganic nanoparticles for targeted drug delivery. In: Biointegration of Medical Implant Materials, pp.333-373.
40. Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R. and Langer, R., 2007. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), pp.751-760.
41. Petros, R.A. and DeSimone, J.M., 2010. Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), pp.615-627.
42. Rehman, N. and Pandey, A., 2022. Introduction to nanotherapeutics: a synthetic preview. In: Nanotherapeutics in Cancer, pp.1-22.
43. Shi, J., Kantoff, P.W., Wooster, R. and Farokhzad, O.C., 2017. Cancer nanomedicine: progress, challenges, and opportunities. Nature Reviews Cancer, 17(1), pp.20-37.
44. Svenson, S. and Tomalia, D.A., 2005. Dendrimers in biomedical applications—reflections on the field. Advanced Drug Delivery Reviews, 57(15), pp.2106-2129.
45. Thakuria, A., Kataria, B. and Gupta, D., 2021. Nanoparticle-based methodologies for targeted drug delivery—an insight. Journal of Nanoparticle Research, 23(4), p.87.
46. Torchilin, V.P., 2005. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), pp.145-160.
47. Wagner, A.M., Gran, M.P. and Peppas, N.A., 2018. Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery. Acta Pharmaceutica Sinica B, 8(2), pp.147–164.
48. Wechsler, M.E., Vela Ramirez, J.E. and Peppas, N.A., 2019. Nanoparticle-mediated drug delivery for the treatment of Alzheimer’s disease: crossing the blood–brain barrier. Industrial & Engineering Chemistry Research, 58(30), pp.13554-13564.
49. Wilhelm, S., Tavares, A.J., Dai, Q., Ohta, S., Audet, J., Dvorak, H.F. and Chan, W.C., 2016. Analysis of nanoparticle delivery to tumors. Nature Reviews Materials, 1(5), p.16014.
50. Zhuang, J., Holay, M., Park, J.H., Fang, R.H., Zhang, J. and Zhang, L., 2019. Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy. Theranostics, 9(25), pp.7826-7848.
Published
2024-09-30
How to Cite
Nikandish, M., Wang, H., Bao, X., & Nikandish, M. (2024). Advancements in Nanoparticle-Based Precision Drug Delivery: A Review of Development and Optimization for Targeted Therapy in Preclinical Models. European Scientific Journal, ESJ, 20(27), 49. https://doi.org/10.19044/esj.2024.v20n27p49
Section
ESJ Natural/Life/Medical Sciences
Copyright (c) 2024 Mehrasa Nikandish, Hanzhi Wang, Xinqi Bao, Mohamad Nikandish
This work is licensed under a Creative Commons Attribution 4.0 International License.
.jpg)
